Allworth Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Allworth Financial’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.2K	Buy	1,276 +29	+2%	+$966	﹤0.01%	2612
2026 Q1	$37.6K	Buy	1,247 +306	+33%	+$9.85K	﹤0.01%	2542
2025 Q4	$29.4K	Buy	941 +329	+54%	+$8.11K	﹤0.01%	2558
2025 Q3	$12.4K	Buy	612 +142	+30%	+$2.49K	﹤0.01%	3005
2025 Q2	$7.88K	Buy	470 +95	+25%	+$1.53K	﹤0.01%	3011
2025 Q1	$5.52K	Sell	375 -7	-2%	-$125	﹤0.01%	2706
2024 Q4	$8.41K	Sell	382 -130	-25%	-$2.37K	﹤0.01%	2511
2024 Q3	$9.23K	Buy	512 +200	+64%	+$3.5K	﹤0.01%	2298
2024 Q2	$5.25K	Buy	312 +3	+1%	+$46	﹤0.01%	2499
2024 Q1	$4.36K	Buy	309 +180	+140%	+$2.27K	﹤0.01%	2462
2023 Q4	$1.35K	Sell	129 -9	-7%	-$84	﹤0.01%	2846
2023 Q3	$1.41K	Sell	138 -914	-87%	-$8.51K	﹤0.01%	2706
2023 Q2	$7.92K	Buy	1,052 +600	+133%	+$4.87K	﹤0.01%	1933
2023 Q1	$4K	Hold	452	–	–	﹤0.01%	2130
2022 Q4	$4.12K	Hold	452	–	–	﹤0.01%	1967
2022 Q3	$4K	Hold	452	–	–	﹤0.01%	1975
2022 Q2	$3K	Hold	452	–	–	﹤0.01%	1939
2022 Q1	$4K	Buy	452 +100	+28%	+$835	﹤0.01%	1686
2021 Q4	$3K	Hold	352	–	–	﹤0.01%	1677
2021 Q3	$3K	Hold	352	–	–	﹤0.01%	1629
2021 Q2	$3K	Hold	352	–	–	﹤0.01%	1331
2021 Q1	$4K	Hold	352	–	–	﹤0.01%	1201
2020 Q4	$3K	Sell	352 -3	-0.8%	-$29	﹤0.01%	1101
2020 Q3	$3K	Hold	355	–	–	﹤0.01%	952
2020 Q2	$4K	Hold	355	–	–	﹤0.01%	916
2020 Q1	$3K	Hold	355	–	–	﹤0.01%	1005
2019 Q4	$3K	Buy	355 +3	+0.9%	+$27	﹤0.01%	863
2019 Q3	$2K	Hold	352	–	–	﹤0.01%	851
2019 Q2	$3K	Sell	352 -84	-19%	-$1.01K	﹤0.01%	776
2019 Q1	$7K	Hold	436	–	–	﹤0.01%	627
2018 Q4	$7K	Hold	436	–	–	﹤0.01%	580
2018 Q3	$9K	Hold	436	–	–	﹤0.01%	577
2018 Q2	$11K	Hold	436	–	–	﹤0.01%	513
2018 Q1	$7K	Hold	436	–	–	﹤0.01%	542
2017 Q4	$8K	Buy	436 +1	+0.2%	+$15	﹤0.01%	509
2017 Q3	$8K	Hold	435	–	–	﹤0.01%	507
2017 Q2	$14K	Hold	435	–	–	﹤0.01%	432
2017 Q1	$14K	Buy	435 +83	+24%	+$2.83K	﹤0.01%	411
2016 Q4	$13K	Hold	352	–	–	﹤0.01%	370
2016 Q3	$16K	Hold	352	–	–	﹤0.01%	356
2016 Q2	$18K	Hold	352	–	–	﹤0.01%	322
2016 Q1	$19K	Hold	352	–	–	﹤0.01%	315
2015 Q4	$23K	Sell	352 -523	-60%	-$32.3K	﹤0.01%	289
2015 Q3	$49K	Buy	875 +352	+67%	+$22.8K	0.02%	212
2015 Q2	$31K	Hold	523	–	–	0.01%	257
2015 Q1	$33K	Buy	+523	New	+$30.4K	0.01%	245

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Allworth Financial's TEVA Position: Q2 2026 in Review

Allworth Financial increased its Teva Pharmaceuticals (TEVA) stake by 2.3% in Q2 2026, buying an estimated $966 and bringing the position to 1,276 shares worth $43.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2612.

Allworth Financial first reported a position in TEVA in Q1 2015 and has held it in 46 quarters since. The position peaked at $49K in Q3 2015. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Allworth Financial held 1,276 shares of Teva Pharmaceuticals worth $43.2K as of Q2 2026.
Allworth Financial bought 29 Teva Pharmaceuticals shares in Q2 2026, an estimated $966.
Teva Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2612 holding.
Allworth Financial first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 46 quarters since.
Allworth Financial's Teva Pharmaceuticals position peaked at $49K in Q3 2015.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.